Feksofenadin
Nama sistematis (IUPAC) | |
---|---|
(±)-4-[1-Hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-butyl]-α, α-dimethyl benzeneacetic acid | |
Data klinis | |
Nama dagang | Allegra, others |
AHFS/Drugs.com | monograph |
MedlinePlus | a697035 |
Data lisensi | US Daily Med:pranala |
Kat. kehamilan | B2(AU) |
Status hukum | Apotek saja (S2) (AU) OTC (CA) P (UK) OTC (US) |
Rute | By mouth |
Data farmakokinetik | |
Bioavailabilitas | 30–41%[1] |
Ikatan protein | 60–70%[2] |
Metabolisme | Hepatic (≤5% of dose)[2] |
Waktu paruh | 14.4 hours |
Ekskresi | Feces (~80%) and urine (~10%) as unchanged drug[2] |
Pengenal | |
Nomor CAS | 83799-24-0 |
Kode ATC | R06AX26 |
PubChem | CID 3348 |
Ligan IUPHAR | 4819 |
DrugBank | DB00950 |
ChemSpider | 3231 |
UNII | E6582LOH6V |
KEGG | D07958 |
ChEBI | CHEBI:5050 |
ChEMBL | CHEMBL914 |
Data kimia | |
Rumus | C32H39NO4 |
|
Feksofenadin[3] adalah obat antihistamin yang digunakan dalam pengobatan gejala alergi, seperti rinitis alergi dan urtikaria.[4]
Secara terapeutik, feksofenadin adalah penghambat H1 perifer selektif. Obat ini diklasifikasikan sebagai antihistamin generasi kedua karena kurang mampu melewati sawar darah otak dan menyebabkan sedasi, dibandingkan antihistamin generasi pertama.[5][6]
Obat ini dipatenkan pada tahun 1979 dan mulai digunakan secara medis pada tahun 1996.[7] Obat ini ada dalam Daftar Obat Esensial Organisasi Kesehatan Dunia.[8] Feksofenadin telah diproduksi dalam bentuk generik sejak 2011.[9]
Sejarah
kegunaan dalam Medis
Efek Samping
Overdosis
Farmakologi
Interaksi
Referensi
- ^ Lappin G, Shishikura Y, Jochemsen R, Weaver RJ, Gesson C, Houston B, Oosterhuis B, Bjerrum OJ, Rowland M, Garner C (May 2010). "Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability". European Journal of Pharmaceutical Sciences. 40 (2): 125–131. doi:10.1016/j.ejps.2010.03.009. PMID 20307657.
- ^ a b c Smith SM, Gums JG (July 2009). "Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders". Expert Opinion on Drug Metabolism & Toxicology. 5 (7): 813–822. doi:10.1517/17425250903044967. PMID 19545214.
- ^ Kesalahan pengutipan: Tag
<ref>
tidak sah; tidak ditemukan teks untuk ref bernamaBrands
- ^ Bachert C (May 2009). "A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis". Clinical Therapeutics. 31 (5): 921–944. doi:10.1016/j.clinthera.2009.05.017. PMID 19539095.
- ^ Compalati E, Baena-Cagnani R, Penagos M, Badellino H, Braido F, Gómez RM, Canonica GW, Baena-Cagnani CE (2011). "Systematic review on the efficacy of fexofenadine in seasonal allergic rhinitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials". International Archives of Allergy and Immunology. 156 (1): 1–15. doi:10.1159/000321896 . PMID 21969990.
- ^ Dicpinigaitis PV, Gayle YE (November 2003). "Effect of the second-generation antihistamine, fexofenadine, on cough reflex sensitivity and pulmonary function". British Journal of Clinical Pharmacology. 56 (5): 501–504. doi:10.1046/j.1365-2125.2003.01902.x. PMC 1884387 . PMID 14651723.
- ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. hlm. 548. ISBN 9783527607495.
- ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533 . WHO/MHP/HPS/EML/2021.02.
- ^ "Dr. Reddy's announces the launch of Over-the-Counter Fexofenadine HCl and Pseudoephedrine HCl extended release tablets". Dr. Reddy's Laboratories Ltd. 30 August 2011. Diarsipkan dari versi asli tanggal 12 October 2016. Diakses tanggal 27 May 2016.